Neurometabolic Disorders Market Report

Global Neurometabolic Disorders Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Mar 11, 2022
  • PAGES：147
  • REPORT CODE：GMM822668
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Neurometabolic Disorders market report explains the definition, types, applications, major countries, and major players of the Neurometabolic Disorders market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Protalix

    • Biomarin

    • Greencross

    • ISU Abxis

    • Genzyme

    • Shire

    • Protalix BioTherapeutics

    • Biosidus

    • JCR Pharmaceuticals

    • Amicus

    • Greenovation Biotech

    • Dong-A Socio Group

    • Pharming Group

    • Amicus Therapeutics

    • Neuraltus Pharmaceuticals

    • Amicus Therapeutics BioTherapeutics

    • UAB Proforma

    • ExSAR Corporation

    By Type:

    • Gaucher’s Disease

    • Fabry Disease

    • Pompe Disease

    • Mucopolysaccharidosis VI

    • Other

    By End-User:

    • Oral

    • Parenteral

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Neurometabolic Disorders Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Neurometabolic Disorders Outlook to 2028- Original Forecasts

    • 2.2 Neurometabolic Disorders Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Neurometabolic Disorders Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Neurometabolic Disorders Market- Recent Developments

    • 6.1 Neurometabolic Disorders Market News and Developments

    • 6.2 Neurometabolic Disorders Market Deals Landscape

    7 Neurometabolic Disorders Raw Materials and Cost Structure Analysis

    • 7.1 Neurometabolic Disorders Key Raw Materials

    • 7.2 Neurometabolic Disorders Price Trend of Key Raw Materials

    • 7.3 Neurometabolic Disorders Key Suppliers of Raw Materials

    • 7.4 Neurometabolic Disorders Market Concentration Rate of Raw Materials

    • 7.5 Neurometabolic Disorders Cost Structure Analysis

      • 7.5.1 Neurometabolic Disorders Raw Materials Analysis

      • 7.5.2 Neurometabolic Disorders Labor Cost Analysis

      • 7.5.3 Neurometabolic Disorders Manufacturing Expenses Analysis

    8 Global Neurometabolic Disorders Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Neurometabolic Disorders Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Neurometabolic Disorders Export by Region (Top 10 Countries) (2017-2028)

    9 Global Neurometabolic Disorders Market Outlook by Types and Applications to 2022

    • 9.1 Global Neurometabolic Disorders Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Gaucher’s Disease Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Fabry Disease Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Pompe Disease Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Mucopolysaccharidosis VI Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Other Consumption and Growth Rate (2017-2022)

    • 9.2 Global Neurometabolic Disorders Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Oral Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Parenteral Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Neurometabolic Disorders Market Analysis and Outlook till 2022

    • 10.1 Global Neurometabolic Disorders Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Neurometabolic Disorders Consumption (2017-2022)

      • 10.2.2 Canada Neurometabolic Disorders Consumption (2017-2022)

      • 10.2.3 Mexico Neurometabolic Disorders Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Neurometabolic Disorders Consumption (2017-2022)

      • 10.3.2 UK Neurometabolic Disorders Consumption (2017-2022)

      • 10.3.3 Spain Neurometabolic Disorders Consumption (2017-2022)

      • 10.3.4 Belgium Neurometabolic Disorders Consumption (2017-2022)

      • 10.3.5 France Neurometabolic Disorders Consumption (2017-2022)

      • 10.3.6 Italy Neurometabolic Disorders Consumption (2017-2022)

      • 10.3.7 Denmark Neurometabolic Disorders Consumption (2017-2022)

      • 10.3.8 Finland Neurometabolic Disorders Consumption (2017-2022)

      • 10.3.9 Norway Neurometabolic Disorders Consumption (2017-2022)

      • 10.3.10 Sweden Neurometabolic Disorders Consumption (2017-2022)

      • 10.3.11 Poland Neurometabolic Disorders Consumption (2017-2022)

      • 10.3.12 Russia Neurometabolic Disorders Consumption (2017-2022)

      • 10.3.13 Turkey Neurometabolic Disorders Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Neurometabolic Disorders Consumption (2017-2022)

      • 10.4.2 Japan Neurometabolic Disorders Consumption (2017-2022)

      • 10.4.3 India Neurometabolic Disorders Consumption (2017-2022)

      • 10.4.4 South Korea Neurometabolic Disorders Consumption (2017-2022)

      • 10.4.5 Pakistan Neurometabolic Disorders Consumption (2017-2022)

      • 10.4.6 Bangladesh Neurometabolic Disorders Consumption (2017-2022)

      • 10.4.7 Indonesia Neurometabolic Disorders Consumption (2017-2022)

      • 10.4.8 Thailand Neurometabolic Disorders Consumption (2017-2022)

      • 10.4.9 Singapore Neurometabolic Disorders Consumption (2017-2022)

      • 10.4.10 Malaysia Neurometabolic Disorders Consumption (2017-2022)

      • 10.4.11 Philippines Neurometabolic Disorders Consumption (2017-2022)

      • 10.4.12 Vietnam Neurometabolic Disorders Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Neurometabolic Disorders Consumption (2017-2022)

      • 10.5.2 Colombia Neurometabolic Disorders Consumption (2017-2022)

      • 10.5.3 Chile Neurometabolic Disorders Consumption (2017-2022)

      • 10.5.4 Argentina Neurometabolic Disorders Consumption (2017-2022)

      • 10.5.5 Venezuela Neurometabolic Disorders Consumption (2017-2022)

      • 10.5.6 Peru Neurometabolic Disorders Consumption (2017-2022)

      • 10.5.7 Puerto Rico Neurometabolic Disorders Consumption (2017-2022)

      • 10.5.8 Ecuador Neurometabolic Disorders Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Neurometabolic Disorders Consumption (2017-2022)

      • 10.6.2 Kuwait Neurometabolic Disorders Consumption (2017-2022)

      • 10.6.3 Oman Neurometabolic Disorders Consumption (2017-2022)

      • 10.6.4 Qatar Neurometabolic Disorders Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Neurometabolic Disorders Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Neurometabolic Disorders Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Neurometabolic Disorders Consumption (2017-2022)

      • 10.7.2 South Africa Neurometabolic Disorders Consumption (2017-2022)

      • 10.7.3 Egypt Neurometabolic Disorders Consumption (2017-2022)

      • 10.7.4 Algeria Neurometabolic Disorders Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Neurometabolic Disorders Consumption (2017-2022)

      • 10.8.2 New Zealand Neurometabolic Disorders Consumption (2017-2022)

    11 Global Neurometabolic Disorders Competitive Analysis

    • 11.1 Protalix

      • 11.1.1 Protalix Company Details

      • 11.1.2 Protalix Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Protalix Neurometabolic Disorders Main Business and Markets Served

      • 11.1.4 Protalix Neurometabolic Disorders Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Biomarin

      • 11.2.1 Biomarin Company Details

      • 11.2.2 Biomarin Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Biomarin Neurometabolic Disorders Main Business and Markets Served

      • 11.2.4 Biomarin Neurometabolic Disorders Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Greencross

      • 11.3.1 Greencross Company Details

      • 11.3.2 Greencross Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Greencross Neurometabolic Disorders Main Business and Markets Served

      • 11.3.4 Greencross Neurometabolic Disorders Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 ISU Abxis

      • 11.4.1 ISU Abxis Company Details

      • 11.4.2 ISU Abxis Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 ISU Abxis Neurometabolic Disorders Main Business and Markets Served

      • 11.4.4 ISU Abxis Neurometabolic Disorders Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Genzyme

      • 11.5.1 Genzyme Company Details

      • 11.5.2 Genzyme Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Genzyme Neurometabolic Disorders Main Business and Markets Served

      • 11.5.4 Genzyme Neurometabolic Disorders Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Shire

      • 11.6.1 Shire Company Details

      • 11.6.2 Shire Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Shire Neurometabolic Disorders Main Business and Markets Served

      • 11.6.4 Shire Neurometabolic Disorders Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Protalix BioTherapeutics

      • 11.7.1 Protalix BioTherapeutics Company Details

      • 11.7.2 Protalix BioTherapeutics Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Protalix BioTherapeutics Neurometabolic Disorders Main Business and Markets Served

      • 11.7.4 Protalix BioTherapeutics Neurometabolic Disorders Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Biosidus

      • 11.8.1 Biosidus Company Details

      • 11.8.2 Biosidus Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Biosidus Neurometabolic Disorders Main Business and Markets Served

      • 11.8.4 Biosidus Neurometabolic Disorders Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    • 11.9 JCR Pharmaceuticals

      • 11.9.1 JCR Pharmaceuticals Company Details

      • 11.9.2 JCR Pharmaceuticals Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

      • 11.9.3 JCR Pharmaceuticals Neurometabolic Disorders Main Business and Markets Served

      • 11.9.4 JCR Pharmaceuticals Neurometabolic Disorders Product Portfolio

      • 11.9.5 Recent Research and Development Strategies

    • 11.10 Amicus

      • 11.10.1 Amicus Company Details

      • 11.10.2 Amicus Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

      • 11.10.3 Amicus Neurometabolic Disorders Main Business and Markets Served

      • 11.10.4 Amicus Neurometabolic Disorders Product Portfolio

      • 11.10.5 Recent Research and Development Strategies

    • 11.11 Greenovation Biotech

      • 11.11.1 Greenovation Biotech Company Details

      • 11.11.2 Greenovation Biotech Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

      • 11.11.3 Greenovation Biotech Neurometabolic Disorders Main Business and Markets Served

      • 11.11.4 Greenovation Biotech Neurometabolic Disorders Product Portfolio

      • 11.11.5 Recent Research and Development Strategies

    • 11.12 Dong-A Socio Group

      • 11.12.1 Dong-A Socio Group Company Details

      • 11.12.2 Dong-A Socio Group Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

      • 11.12.3 Dong-A Socio Group Neurometabolic Disorders Main Business and Markets Served

      • 11.12.4 Dong-A Socio Group Neurometabolic Disorders Product Portfolio

      • 11.12.5 Recent Research and Development Strategies

    • 11.13 Pharming Group

      • 11.13.1 Pharming Group Company Details

      • 11.13.2 Pharming Group Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

      • 11.13.3 Pharming Group Neurometabolic Disorders Main Business and Markets Served

      • 11.13.4 Pharming Group Neurometabolic Disorders Product Portfolio

      • 11.13.5 Recent Research and Development Strategies

    • 11.14 Amicus Therapeutics

      • 11.14.1 Amicus Therapeutics Company Details

      • 11.14.2 Amicus Therapeutics Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

      • 11.14.3 Amicus Therapeutics Neurometabolic Disorders Main Business and Markets Served

      • 11.14.4 Amicus Therapeutics Neurometabolic Disorders Product Portfolio

      • 11.14.5 Recent Research and Development Strategies

    • 11.15 Neuraltus Pharmaceuticals

      • 11.15.1 Neuraltus Pharmaceuticals Company Details

      • 11.15.2 Neuraltus Pharmaceuticals Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

      • 11.15.3 Neuraltus Pharmaceuticals Neurometabolic Disorders Main Business and Markets Served

      • 11.15.4 Neuraltus Pharmaceuticals Neurometabolic Disorders Product Portfolio

      • 11.15.5 Recent Research and Development Strategies

    • 11.16 Amicus Therapeutics BioTherapeutics

      • 11.16.1 Amicus Therapeutics BioTherapeutics Company Details

      • 11.16.2 Amicus Therapeutics BioTherapeutics Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

      • 11.16.3 Amicus Therapeutics BioTherapeutics Neurometabolic Disorders Main Business and Markets Served

      • 11.16.4 Amicus Therapeutics BioTherapeutics Neurometabolic Disorders Product Portfolio

      • 11.16.5 Recent Research and Development Strategies

    • 11.17 UAB Proforma

      • 11.17.1 UAB Proforma Company Details

      • 11.17.2 UAB Proforma Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

      • 11.17.3 UAB Proforma Neurometabolic Disorders Main Business and Markets Served

      • 11.17.4 UAB Proforma Neurometabolic Disorders Product Portfolio

      • 11.17.5 Recent Research and Development Strategies

    • 11.18 ExSAR Corporation

      • 11.18.1 ExSAR Corporation Company Details

      • 11.18.2 ExSAR Corporation Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

      • 11.18.3 ExSAR Corporation Neurometabolic Disorders Main Business and Markets Served

      • 11.18.4 ExSAR Corporation Neurometabolic Disorders Product Portfolio

      • 11.18.5 Recent Research and Development Strategies

    12 Global Neurometabolic Disorders Market Outlook by Types and Applications to 2028

    • 12.1 Global Neurometabolic Disorders Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Gaucher’s Disease Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Fabry Disease Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Pompe Disease Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.4 Global Mucopolysaccharidosis VI Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.5 Global Other Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Neurometabolic Disorders Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Oral Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Parenteral Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Neurometabolic Disorders Market Analysis and Outlook to 2028

    • 13.1 Global Neurometabolic Disorders Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.2.2 Canada Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Neurometabolic Disorders Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.3.2 UK Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.3.3 Spain Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.3.5 France Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.3.6 Italy Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.3.8 Finland Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.3.9 Norway Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.3.11 Poland Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.3.12 Russia Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Neurometabolic Disorders Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.4.2 Japan Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.4.3 India Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Neurometabolic Disorders Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.5.3 Chile Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.5.6 Peru Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Neurometabolic Disorders Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.6.3 Oman Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Neurometabolic Disorders Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Neurometabolic Disorders Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Neurometabolic Disorders Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Neurometabolic Disorders Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Neurometabolic Disorders

    • Figure of Neurometabolic Disorders Picture

    • Table Global Neurometabolic Disorders Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Neurometabolic Disorders Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Gaucher’s Disease Consumption and Growth Rate (2017-2022)

    • Figure Global Fabry Disease Consumption and Growth Rate (2017-2022)

    • Figure Global Pompe Disease Consumption and Growth Rate (2017-2022)

    • Figure Global Mucopolysaccharidosis VI Consumption and Growth Rate (2017-2022)

    • Figure Global Other Consumption and Growth Rate (2017-2022)

    • Figure Global Oral Consumption and Growth Rate (2017-2022)

    • Figure Global Parenteral Consumption and Growth Rate (2017-2022)

    • Figure Global Neurometabolic Disorders Consumption by Country (2017-2022)

    • Table North America Neurometabolic Disorders Consumption by Country (2017-2022)

    • Figure United States Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Canada Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Mexico Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Table Europe Neurometabolic Disorders Consumption by Country (2017-2022)

    • Figure Germany Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure UK Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Spain Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Belgium Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure France Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Italy Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Denmark Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Finland Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Norway Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Sweden Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Poland Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Russia Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Turkey Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Table APAC Neurometabolic Disorders Consumption by Country (2017-2022)

    • Figure China Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Japan Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure India Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure South Korea Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Thailand Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Singapore Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Philippines Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Table South America Neurometabolic Disorders Consumption by Country (2017-2022)

    • Figure Brazil Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Colombia Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Chile Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Argentina Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Peru Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Table GCC Neurometabolic Disorders Consumption by Country (2017-2022)

    • Figure Bahrain Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Oman Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Qatar Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Table Africa Neurometabolic Disorders Consumption by Country (2017-2022)

    • Figure Nigeria Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure South Africa Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Egypt Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure Algeria Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Table Oceania Neurometabolic Disorders Consumption by Country (2017-2022)

    • Figure Australia Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Neurometabolic Disorders Consumption and Growth Rate (2017-2022)

    • Table Protalix Company Details

    • Table Protalix Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

    • Table Protalix Neurometabolic Disorders Main Business and Markets Served

    • Table Protalix Neurometabolic Disorders Product Portfolio

    • Table Biomarin Company Details

    • Table Biomarin Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

    • Table Biomarin Neurometabolic Disorders Main Business and Markets Served

    • Table Biomarin Neurometabolic Disorders Product Portfolio

    • Table Greencross Company Details

    • Table Greencross Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

    • Table Greencross Neurometabolic Disorders Main Business and Markets Served

    • Table Greencross Neurometabolic Disorders Product Portfolio

    • Table ISU Abxis Company Details

    • Table ISU Abxis Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

    • Table ISU Abxis Neurometabolic Disorders Main Business and Markets Served

    • Table ISU Abxis Neurometabolic Disorders Product Portfolio

    • Table Genzyme Company Details

    • Table Genzyme Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

    • Table Genzyme Neurometabolic Disorders Main Business and Markets Served

    • Table Genzyme Neurometabolic Disorders Product Portfolio

    • Table Shire Company Details

    • Table Shire Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

    • Table Shire Neurometabolic Disorders Main Business and Markets Served

    • Table Shire Neurometabolic Disorders Product Portfolio

    • Table Protalix BioTherapeutics Company Details

    • Table Protalix BioTherapeutics Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

    • Table Protalix BioTherapeutics Neurometabolic Disorders Main Business and Markets Served

    • Table Protalix BioTherapeutics Neurometabolic Disorders Product Portfolio

    • Table Biosidus Company Details

    • Table Biosidus Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

    • Table Biosidus Neurometabolic Disorders Main Business and Markets Served

    • Table Biosidus Neurometabolic Disorders Product Portfolio

    • Table JCR Pharmaceuticals Company Details

    • Table JCR Pharmaceuticals Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

    • Table JCR Pharmaceuticals Neurometabolic Disorders Main Business and Markets Served

    • Table JCR Pharmaceuticals Neurometabolic Disorders Product Portfolio

    • Table Amicus Company Details

    • Table Amicus Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

    • Table Amicus Neurometabolic Disorders Main Business and Markets Served

    • Table Amicus Neurometabolic Disorders Product Portfolio

    • Table Greenovation Biotech Company Details

    • Table Greenovation Biotech Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

    • Table Greenovation Biotech Neurometabolic Disorders Main Business and Markets Served

    • Table Greenovation Biotech Neurometabolic Disorders Product Portfolio

    • Table Dong-A Socio Group Company Details

    • Table Dong-A Socio Group Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

    • Table Dong-A Socio Group Neurometabolic Disorders Main Business and Markets Served

    • Table Dong-A Socio Group Neurometabolic Disorders Product Portfolio

    • Table Pharming Group Company Details

    • Table Pharming Group Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pharming Group Neurometabolic Disorders Main Business and Markets Served

    • Table Pharming Group Neurometabolic Disorders Product Portfolio

    • Table Amicus Therapeutics Company Details

    • Table Amicus Therapeutics Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

    • Table Amicus Therapeutics Neurometabolic Disorders Main Business and Markets Served

    • Table Amicus Therapeutics Neurometabolic Disorders Product Portfolio

    • Table Neuraltus Pharmaceuticals Company Details

    • Table Neuraltus Pharmaceuticals Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

    • Table Neuraltus Pharmaceuticals Neurometabolic Disorders Main Business and Markets Served

    • Table Neuraltus Pharmaceuticals Neurometabolic Disorders Product Portfolio

    • Table Amicus Therapeutics BioTherapeutics Company Details

    • Table Amicus Therapeutics BioTherapeutics Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

    • Table Amicus Therapeutics BioTherapeutics Neurometabolic Disorders Main Business and Markets Served

    • Table Amicus Therapeutics BioTherapeutics Neurometabolic Disorders Product Portfolio

    • Table UAB Proforma Company Details

    • Table UAB Proforma Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

    • Table UAB Proforma Neurometabolic Disorders Main Business and Markets Served

    • Table UAB Proforma Neurometabolic Disorders Product Portfolio

    • Table ExSAR Corporation Company Details

    • Table ExSAR Corporation Neurometabolic Disorders Sales, Price, Value and Gross Profit (2017-2022)

    • Table ExSAR Corporation Neurometabolic Disorders Main Business and Markets Served

    • Table ExSAR Corporation Neurometabolic Disorders Product Portfolio

    • Figure Global Gaucher’s Disease Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Fabry Disease Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Pompe Disease Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Mucopolysaccharidosis VI Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Other Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Oral Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Parenteral Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Neurometabolic Disorders Consumption Forecast by Country (2022-2028)

    • Table North America Neurometabolic Disorders Consumption Forecast by Country (2022-2028)

    • Figure United States Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Neurometabolic Disorders Consumption Forecast by Country (2022-2028)

    • Figure Germany Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Neurometabolic Disorders Consumption Forecast by Country (2022-2028)

    • Figure China Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Neurometabolic Disorders Consumption Forecast by Country (2022-2028)

    • Figure Brazil Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Neurometabolic Disorders Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Neurometabolic Disorders Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Neurometabolic Disorders Consumption Forecast by Country (2022-2028)

    • Figure Australia Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Neurometabolic Disorders Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US